Source: PharmaDJ

Author: Huanmu     Editor: Vitamin

Table 1. Top 10 Pharmaceutical Giants in H1 2025 Revenue Rankings, Source:Drug Export

From the "report cards" of major pharmaceutical companies in the first half of the year,Only One Breakthrough400The 100 million US dollars mark, namely Johnson & Johnson.The company's total revenue reached456.36Billion US dollars, year-on-year growth4.1%, demonstrating a steady development trend. Among them, the innovative pharmaceuticals business contributed290.75Billion USD in revenue, with a growth rate of3.6%; Medical technology business revenue is165.61Billion USD, Growth5.0%。

In the innovative pharmaceuticals business, the oncology sector has performed particularly well, becoming the core driver of growth.Daratumumab2025Sales in the first half of the year soared to67.76billion US dollars, increased by21.7%, accounting for the total revenue of the tumor business56%。CAR-TProductCarvyktiThe growth momentum is equally rapid, becoming another powerful engine for the growth of the oncology business. In the first half of the year,CarvyktiSales reached8.08Billion US dollars, has exceeded2024Annual sales for the year in China.

Closely FollowSubsequentIt's Roche,2025In the first half of the year, the total revenue was approximately372.76Billion US dollarsIn terms of pharmaceuticals business, Roche achieved approximately280.72Billion US dollars, an increase of approximately10%。

Among them,Breast Cancer MedicationsPhesgoContribution Income14.83Billion USD, Growth55%；Hematological Cancer DrugsPolivySales amount to9.04billion USD, with an increase of46%；For asthma and food allergiesOmalizumabGrowth in Drug Sales Revenue34%, reaching17.90USD billion, diversified product portfolio drives Roche's continuous growth and expansion.

MSD Announces2025The performance report for the first half of the year shows that the total revenue achieved during the period was313.35Billion US dollars, a year-on-year decrease2%; including pharmaceuticals revenue276.88Billion USD, a year-on-year decrease3%Notably, the performance in the China region has been significantly pressured, with revenue in the first half of the year declining year-over-year.70%To10.75billion USD, accounting for a decrease in Merck's global pharmaceutical business3.9%。

From the perspective of core products, as the pillar of the company's revenue“Medicine King”Keytruda（KDrug, Pembrolizumab), sales in the first half of the year reached151.61billion dollars, accounting for nearly half of the total revenue (48.38%), Year-on-year growth7%, but in contrast2024The first half of the year18%The growth rate, its momentum has shown a slowing trend. Another flagship productHPVVaccineGardasil/Gardasil9Suboptimal performance,Sales in the first half of the year were24.53billion US dollars, a significant year-on-year decrease48%。

Facing performance pressure, Merck has launched a new multi-year optimization plan aimed at enhancing productivity and achieving anticipated results.2027Year-end annual savings30The target of saving billions of dollars in costs will further drive the transformation of the product portfolio. According to reports, the saved costs will be entirely allocated to the launch of new products across multiple therapeutic areas and investment in the R&D pipeline.

Pfizer2025Cumulative Revenue for the First Half of the Fiscal Year283.67Billion US dollars, year-on-year growth0.73%In terms of business segments, the three major businesses—Oncology, Primary Care, and Specialty Care—generated revenues respectively in the first half of this year.81.45Billion USD (+9%）、112.36Billion USD (-8%）、83.64Billion USD (+6%）。

The heavyweights in the oncology field are still the blockbuster drugs for breast cancer.Ibrance(Palbociclib,CDK4/6Inhibitors), although its sales have been declining due to fierce competition, it still had20.26Billion-dollar volume.

Pfizer in2023By the end of the year430Billion-dollar acquisitionSeagenThe products obtained are mostly in the growth phase, and the combined revenue of these products in the first half of this year is approximately17.52Billion US dollars, of whichADCTotal products approximately15.18Billion US dollars.

Eli Lilly Releases Financial Report,2025Cumulative Revenue for the First Half of the Fiscal Year282.86Billion US dollars, year-on-year growth40.93%。Diabetes Business Contributes Nearly Half of Eli Lilly's Revenue, among whichTrulicity、Mounjaro、HumalogAndJardianceThe Combined Contribution of Four Products139.728Billion US dollars.And the real engine driving performance growth isGLP-1/GIPDual-target AgonistTirzepatide——Its Hypoglycemic VersionMounjaroAnd Weight Loss EditionZepboundTotal sales reached in the first half of the year147.34Billion US dollars.

AstraZenecaHalfAnnual FinanceReportData shows that the company achieved a total revenue in the first half of the year.280.45Billion US dollars, an increase of over the same period last year11%. Among which, the product revenue reached266.7billion dollars, an increase of10%. In terms of operating profit, the first half of the year reached71.82Billion USD, year-on-year growth24%。

In terms of products, hypoglycemic drugsDapagliflozin（Farxiga) was the "top seller" in the first half of the year, with revenue in the first half of the year42.09USD billion, a year-on-year increase of13%; Anti-cancer drugsOsimertinib（Tagrisso) followed closely, with revenue in the first half of the year34.88Billion USD, Year-on-Year Growth10%；PD-L1InhibitorDurvalumab（Imfinzi) Income27.16 Billion USD, Year-on-Year Growth21%。

Novartis 2025Net sales for the first half of the year were272.87Billion US dollars, year-on-year growth13%. In terms of specific products,Entresto(Sacubitril/Valsartan) still contributed to the majority of Novartis' revenue,2025Sales in the first half of the year were46.18Billion USD, year-on-year growth22%。

Scemblix、Leqvio、KisqaliThese are the top three products in terms of year-on-year growth rate, with respective year-on-year increases of78%、66%And60%. Another noteworthy aspect is the sales of its nuclear medicine products, with Novartis currently having two commercialized nuclear medicine products.PluvictoAndLutatheraIn the first half of the year, these two products generated revenue respectively.8.25Billion US dollars and4.00Billion US dollars, totaling12.25Billion US dollars.

BMSRelease financial report,2025Cumulative Revenue for the First Half of the Year234.70Billion US dollars，The cumulative revenue for the same period last year was240.66Billion USD, a year-on-year decrease2.48%The main reason is due to the impact of increased generic drug competition and adjustments in U.S. health insurance policies on mature product portfolios, such as anticoagulant drugs.EliquisSales of drugs for treating multiple myeloma decrease in the U.S. marketRevlimidRevenue decreased year-on-year due to generic drug competition44%。

Bristol-Myers Squibb is banking on a series of new drugs to offset the gradually declining sales of its older blockbuster medications. The company plans to2027Cut by about before the year35Billion-dollar expenditures, including layoffs2000Many people have abandoned more than a dozen drugs under development.

Novo NordiskCompany Announcement2025The financial report for the first half of the year shows that Novo Nordisk's total revenue for the first half of the year was approximately228.54Billion US dollars, an increase of over last year18%Among which, the income from the Chinese market is approximately14.62Billion USD, year-on-year growth6%。

Semaglutide（semaglutide) The sales volume reached in the first half of the year166.32billion dollars, accounting for73%. The sales of this drug have surpassedKMedicine (Keytruda) of151.61billion dollars. However, Eli Lilly's tirzepatide has also shown astonishing growth momentum, with total sales in the first half of the year reaching147.34billion dollars. This may make it one of the semaglutide products in2025Year“Medicine King”The main competitor in the battle for market share.